At least 139 funded projects have focused on precision medicine since the council began awarding the grants in 2011, ...

The firm will pick two lead agents targeting PSMA and CLDN18.2 later this year and a third STEAP1-targeting drug next year.

If there are no dose-limiting toxicities, the company will test the CAR T-cell therapy at higher doses in more patients with FLT3-expressing refractory AML.

BUFFALO, New York – Five major research centers in New York have banded together to share resources and a manufacturing ...

SNUG01 showed favorable safety and signs of early clinical efficacy in a recently completed investigator-initiated trial in China, the firm said.

Sarepta will sell back $50 million worth of shares to cover part of a $100 million milestone payment and its remaining shares worth $174 million.

NEW YORK – Prelude Therapeutics will hold back on further developing its SMARCA2 degrader PRT3789 after seeing results from a Phase I study in cancer patients with SMARCA4 mutations, the company ...

Fifteen percent of patients who received Skysona within clinical trials have since been diagnosed with hematologic malignancies.

The Rare Therapies Launch Pad pilot aims to create a streamlined path to develop individualized treatments and get them approved.